Cory Sejo, MD

1/ Advanced platelet therapy by Dr. @MarcBonaca at #HeartofCardiology

Alex Pretti was murdered.

ICYMI! Read-up on the highlights from @ChiHForum #ChiHemos2025 Thank you to the @CardioNerds, @AHajduczok, & @JCardFail team for putting this together! Save-the-Date for the 3rd Annual @ChiHForum: 11/6/2026! @CocoSejo @RSteinbergMD @catweneboah onlinejcf.com/article/S1071-…

#EHJCVI When should we use #EchoFirst in cardiovascular emergencies and critical care? The new EACVI–ACVC consensus highlights its key role in cardiogenic shock, AMI, ADHF, and more 🚨🫀📘 👉 Read more: doi.org/10.1093/ehjci/… @EACVIPresident @ACVCPresident

Session 4 of @ChiHForum focuses on the good, the bad, and the ugly of LVAD hemodynamics, with sessions focused on pre-LVAD assessment, hemodynamics with LVAD complications, and the prediction of cardiac recovery. #ChiHemos2025 @CardioNerds

Hype for hemodynamics! #ChiHemos2025 @catweneboah @RSteinbergMD @CardioNerds

Session 1: Beyond Baseline Hemodynamics at @ChiHForum off to a strong start! 🦾 Check out a few highlights from the session here: #ChiHemos2025 @CardioNerds

Anthony P. Carnicelli, MD, provides a good framework for evaluation and management of PAH in the ICU! 1) Airway mgmt- just the right PEEP 2) MCS - VA ECMO >>> RV-only support. 3) Serial HDs are helpful to guide tx @RyanTedfordMD 4) New meds - role unclear - TBD #ChiHemos2025

Engaging analysis of measuring RV reserve with @cla_baratto! 📌 Invasive PV loops are best, but challenging 📌 Echo via TAPSE/PASP --> simple, precise, but open to criticism 📌 Dynamic assessment with exercise 🗝️ For evaluation: "Something is better than nothing" #ChiHemos2025

Additional nice takeaways for management and risk stratification! From @Jonathan_PaulMD #ChiHemos2025

@Jonathan_PaulMD provides a fantastic talk on HD changes seen in acute PE. 🗝️ Intermediate risk patients are sicker than you may think. 🗝️ Metrics for risk: PESI, RV/LV ratio, TTE. All imperfect. 🗝️ Hemodynamics can help stratify risk! #ChiHemos2025

🗝️ Targeting compliance may be a better metric and future goal to improve outcomes!

Dr. Marc R. Pritzker, MD walks us through changing perspectives in our treatment targets for PAH. 📌Trials focus on vasodilators with modest effect 📌PVR not well associated with outcomes--> but compliance does! #ChiHemos2025

After months of Zoom calls and emails, great to spend time in-person with the Guest Editors of the @JCardFail Focus Issue on Hemodynamics @ChiHForum #ChiHemos2025 Check out the issue here! onlinejcf.com/current

Current testing with vasodilators or response to LV unloading (with Impella), with subsequent improvement in PAPi, can predict good RV outcomes. 🗝️ RV failure after LVAD remains difficult to predict, and it requires ongoing investigation. #ChiHemos2025

@JTThibs provides wonderful context for how to predict RV failure after LVAD so that we may avoid it. 📌 Various scores: (RVSWI, CVP/PCWP/PAPi) 📌 Integrating these scores is helps only modestly (max c-statistic around 0.75 with STOP-RVF) pubmed.ncbi.nlm.nih.gov/38294795/ #ChiHemos2025

🎯Excercise wedge pressure-flow relationships are highly diagnostic and prognostic 🎯Excercise hemodynamic testing is safe, feasible and powerful 🎯improves diagnostic accuracy for HFpEF, deeper physiologic phenotyping, and identifies deficits limiting pts exercise capacity

#ChiHemos2025 The Advanced Analysis of PV Loops with Dr. Dan Burkoff @ChiHForum @CardioNerds 👉As PV Loops move toward routine clinical use , we must interpret correctly 👉Ees alone is not enough ; Vo matters, esp after interventions like TAVR

@BurkhoffMd provides fantastic context for understanding how to critically analyze PV loops! ⚡️ Goal/hope: PV loops will arrive in clinical practice ⚡️ Understanding derivations and assumptions will be critical for interpreting PV loops #ChiHemos2025

For further reading : journals.physiology.org/doi/epdf/10.11… Informative Tweetorial by @AHajduczok ➡️: x.com/ahajduczok/sta…